Exosomes – Pipeline Insight, 2020

September 2020 | 110 pages | ID: EE54BE3C5E6FEN
DelveInsight

Abstracts

This report can be delivered to the clients within 72 - 96 Hours

DelveInsight’s, “Exosomes – Pipeline Insight, 2020” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Exosomes Understanding

Exosomes: Overview

Exosomes are small membrane vesicles of endocytic origin that are secreted by most cells in culture and are created upon the fusion of the multivesicular body (MVB)—an intermediate endocytic compartment—with the plasma membrane. They are nano-sized vesicles capable of transferring DNAs, micro RNAs, non-coding RNAs, and lipids, with or without direct cell-to-cell contact, which represents a novel method of intracellular communication. MVB—a type of intraluminal vesicles (ILV’s)—buds inward into the endosomal lumen. Exosomes, produced in endosomal compartment of most eukaryotic cells, are released in the form of ILV’s in instances where the MVB fuses with the cell surface (the plasma membrane). The exosomes and other extracellular vesicles (EV’s) are present in tissues of the multicellular organisms, including biological fluids, such as blood, urine, and cerebrospinal fluid. They can also be released in vitro by the cultured cells into their growth medium.

Characteristics of Exosomes and Function

Exosomes are basically formed by the cellular endocytic pathway, which consists of three different stages:

• The plasma membrane invagination from the endocytic vesicles.
• The second stage is the inward building of endosomal membrane which gives rise to multivesicular bodies (MVB’s).
• The third and the last stage is when the MVB’s fuse with the plasma membrane and releases the vesicular contents, which in turn forms the exosomes.

The membrane proteins, which undergo the endosomal pathway, exhibit the same stages. Different types of lipidic molecules are known for their involvement in the exosome formation and release like phosphatidic acid and ceramides.

Composition

Due to its protein and lipid content, exosomes are special, providing an additional hint for their identification. Exosomes mainly include fusion and transport proteins (annexins and flotillin), heat shock proteins (HSP70), CDнs proteins (CD9, CD81), and phospholipases and other lipid-related proteins. Due to its protein and lipid content, exosomes are special, providing an additional hint for their identification. Exosomes mainly include fusion and transport proteins (annexins and flotillin), heat shock proteins (HSP70), CDнs proteins (CD9, CD81), and phospholipases and other lipid-related proteins. One can use all of these proteins as positive markers.

Biological functions of Exosomes

Exosomes are nano-sized EVs that have impressive physiological properties and emerge through the inward budding of the late endosomal membrane called multivesicular bodies (MVBs). As MVBs are fused with the plasma membrane, exosomes are released into the extracellular environment. They can either be taken up by target cells residing in the microenvironment or transported by biological fluids to distant sites. Exosomes have a small diameter range of 40–100 nm and a density of 1.13–1.19 g/ml in sucrose solution. They can be sedimented at 100,000 g by centrifugation. Also, exosome membranes are enriched with proteins from cholesterol, sphingomyelin, ceramide and lipid raft.

Exosomes Emerging Drugs Chapters

This segment of the Exosomes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Exosomes Emerging Drugs

• Neural exosomes (AB126): ArunA Biomedical

ArunA Biomedical’s proprietary neural exosomes cross the blood–brain barrier inherently and enable drugs and drug-combinations to naturally target cells and treat patients with a range of neurological disorders. Preclinical studies have demonstrated the therapeutic potential of these exosomes in multiple stroke models. These studies have shown that the exosomes enhance the nervous system’s self-repair mechanisms, translating into structural and functional benefits which may have improved survival, reduced infarct size, and improved mobility.

• ExoPr0: ReNeuron

Company’s CTX-derived exosomes candidate is currently in the preclinical stage and is being developed as a novel vector for delivering the third party biological drugs. ExoPr0 has demonstrated potential as both a novel therapeutic candidate as well as a drug delivery vehicle in established preclinical disease models. The company intends to devote more significant resource to the application of ExoPr0 as a vector for delivering drugs.

• exoIL-12: Codiak Biosciences

exoIL-12 is a precision-engineered exosome therapeutic candidate expressing IL-12 on the surface of the exosome by molecular fusion to Codiak’s proprietary scaffold protein, PTGRFN. Developed via Codiak’s proprietary engEx platform, exoIL-12 is designed to target T-cells and Natural Killer cells and induce systemic anti-tumor immunity. Data from Codiak’s preclinical studies suggest that when administered intratumorally, exoIL-12 is retained in the tumor microenvironment, thus resulting in potent antitumor immunity and an improved toxicity profile compared to recombinant IL-12.

Further product details are provided in the report……..

Exosomes: Therapeutic Assessment

This segment of the report provides insights about the different Exosomes based drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Exosomes

There are approx. 50+ key companies which are developing the therapies for Exosomes. The companies which have their Exosomes drug candidates in the early stages, i.e. phase I include United Therapeutics Corporation.

• Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late-stage products (Phase II and Phase II/III)
• Mid-stage products (Phase II and Phase II/III)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intramuscular
• Intranasal
• Parenteral
• Intravenous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Vaccines
• Polymers
• Peptides
• Enzymes
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Exosomes: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Exosomes therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Exosomes drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Exosomes R&D. The therapies under development are focused on novel approaches to treat/improve Exosomes.
• Anjarium’s Hybridosome platform, coupled with the targeting technology and proprietary manufacturing methods, is a promising technology to overcome the delivery hurdles today’s most potent RNA therapeutic candidates face.
• Therapeutic Benefits: Exosomes are directly internalized by recipient cells, which prevent a multiplicity of potential concerns associated with the administration of living cells, and exosomes have therapeutic benefits, at least equivalent to their cellular source.

Exosomes Report Insights

• Exosomes Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Exosomes Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Exosomes drugs?
• How many Exosomes drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Exosomes?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Exosomes therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Exosomes and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Direct Biologics
• Codiak BioSciences
• ExoCyte Therapeutics
• Avalon GloboCare
• United Therapeutics Corporation
• Capricor Therapeutics
• Avalon GloboCare
• Azymus Therapeutics
• Versatope Therapeutics
• Lamellar Biomedical
• Celltrion

Key Products

• LAMELLASOME IPF-NA
• exoSTING
• ET-08
• AVA 201
• Unexisome
• CAP 2003
• exoIL 12
• AVA 203
• AZ 001
• VT 105

Contents

Introduction
Executive Summary
Exosomes: Overview
  Characteristics of Exosomes and Function
o Formation
  Extracellular vesicles
  Composition
  Exosome Release
  Exosome Uptake
  Biological functions of Exosomes
  Exosomes as a therapeutic target
  Isolation and Characterisation of Exosomes
  Therapeutic Preparation of Exosomes
  Biomedical application
o Exosomes in CNS Disease
o Exosomes in Oncology
o Exosomes in Other Diseases
  Advantages and disadvantages
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Exosomes – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
  Exosomes companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Exosomes Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase I/II)
  Comparative Analysis
MPCs-derived exosomes: Cellular Biomedicine Group Ltd.
  Product Description
  Research and Development
  Product Development Activities
AGLE 102: Aegle Therapeutics
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
  Comparative Analysis
exoSTING: Codiak BioSciences
  Product Description
  Research and Development
  Product Development Activities
AVA 201: Avalon GloboCare
  Product Description
  Research and Development
  Product Development Activities
UNEX 42: United Therapeutics Corporation
  Product Description
  Research and Development
  Product Development Activities
CAP 2003: Capricor Therapeutics
  Product Description
  Research and Development
  Product Development Activities
AB 126: ArunA Biomedical
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  Comparative Analysis
Exosomes Key Companies
Exosomes Key Products
Exosomes- Unmet Needs
Exosomes- Market Drivers and Barriers
Exosomes- Future Perspectives and Conclusion
Exosomes Analyst Views
Exosomes Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Exosomes
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Exosomes
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products